Lyell Immunopharma, Inc.
LYEL
$12.86
$0.161.26%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -24.15M | -140.72M | -38.85M | -42.68M | -52.20M |
| Total Depreciation and Amortization | 2.33M | 2.40M | 2.57M | 3.14M | 3.44M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -15.61M | 105.40M | 7.84M | 5.97M | 3.57M |
| Change in Net Operating Assets | -1.08M | 672.00K | -136.00K | -876.00K | -9.55M |
| Cash from Operations | -38.51M | -32.25M | -28.58M | -34.46M | -54.74M |
| Capital Expenditure | -89.00K | -304.00K | -62.00K | -168.00K | -246.00K |
| Sale of Property, Plant, and Equipment | -- | 24.00K | 263.00K | -- | -- |
| Cash Acquisitions | -- | -41.20M | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 17.47M | 10.11M | 3.15M | 12.82M | 69.71M |
| Cash from Investing | 17.38M | -31.37M | 3.35M | 12.65M | 69.47M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 51.72M | 223.00K | 50.00M | 184.00K | -- |
| Repurchase of Common Stock | -- | -1.00K | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -1.00K | 1.00K |
| Cash from Financing | 51.72M | 222.00K | 50.00M | 183.00K | 1.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 30.59M | -63.39M | 24.77M | -21.63M | 14.73M |